All three tenses have at least two readings, so the archetype blend applies as printed.
Of the nine metrics, 8 read as filed from the record and 1 is an SI estimate, each with its reasoning, its confidence and what would change it on its card.
What did they actually do?
Has it survived what it has been through?
5 warning events since 2017; the latest 2026-10-06.
From the record
Kyntra Bio, Inc.'s filings since 2017 show 5 warning events: a notice about its exchange listing (8-K item 3.01, 5 times, the latest 2026-10-06) (its current reports).
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What has it actually done, year after year?
-31.1% a year over 10 filed years; profitable in 1 of 10.
From the record
Kyntra Bio, Inc.'s 10 filed years say what it did: revenue went from $183 million in fiscal 2016 to $6 million in fiscal 2025, down 31.1% a year; it rose in 3 of 9 years; the deepest fall was 97% from fiscal 2019 to fiscal 2025; net income was positive in 1 of 10 of those years (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How has it treated the people who own it?
SI estimate 7.8/10, confidence 35 of 100 (one part).
SI estimate Inferred, not read as filed
From the record
SI estimate, not a filed reading: Kyntra Bio, Inc.'s shareholder treatment is put at 7.8 of 10 with a confidence of 35 of 100, because read from one part only, the share count over the years, which ranks in the top 21% of 464 in its family; fewer than two of the parts can be read: the share count over the years, and the cash returned against a positive operating cash flow or net income. A filing that carries the missing parts replaces this estimate with the filed reading.
What are they doing right now?
Is it financially healthy right now?
Leverage 114%: owes 114¢ per asset dollar.
From the record
Return on equity: in the fiscal year ended 2025-12-31, Kyntra Bio, Inc.'s shareholders' equity was below zero, so the profit on it is not read, and gross profitability: its products earned about 5 cents per dollar of everything the company owns (revenue less the cost of revenue). Leverage: it owed about 114 cents per dollar of assets, and net share issuance: its share count grew 1.0% over the year (the filed statements).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
How strong is its position in its industry?
bottom 47% of 315 in its family; net margin 2848.6%.
From the record
Kyntra Bio, Inc.'s standing among 315 graded names in its industry family: revenue of $6 million in fiscal 2025 ranks in the bottom 36% by size; a net margin of 2848.6% ranks in the top 1%; revenue growth of -64.2% a year over the last 3 filed years ranks in the bottom 6% (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are the people in charge doing?
bottom 39% of 315 in its family for leadership; chief executive since 2023.
From the record
Kyntra Bio, Inc.'s leadership, from its insiders' filings and its current reports: the chief executive on the record is Wettig, Thane (CEO, as filed), filing under that title since 2023-09-08, 3.2 years (bottom 35% of its family); the 7 officers and directors filing in the last fifteen months have been on the record a median of 6.4 years (top 35%); 6 officer or director changes were reported on Form 8-K since 2023-11-13, against the 7 people in charge now (bottom 17%; fewer changes for each person reads higher) (the Form 4 record, its Form 8-K reports). Years count from a person's first filing in the SEC's data sets, which begin in 2006, so each is a floor.
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What are they set up to do next?
How much room does it have to grow?
top 33% of 273 in its family for room to expand.
From the record
Kyntra Bio, Inc.'s room to grow, from the newest filed statements (fiscal 2025): cash of $48 million against no long-term debt tagged leaves 40% of its assets as net cash, top 39% of its family; cash from operations less capital spending is -74.7% of revenue (top 48%); a gross margin of 91.4% (top 12%); research spending of 365.2% of revenue (top 34%) (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
What could actually drive growth from here?
bottom 8% of 306 in its family for growth drivers.
From the record
Kyntra Bio, Inc.'s growth drivers, from the filed years to fiscal 2025: revenue grew -64.2% a year over the last three filed years against -31.1% over all 10, slowing (bottom 17% of its family); the newest year grew -78.3% (bottom 7%); research spending grew -57% a year (bottom 3%); capital spending grew -78.3% a year (bottom 3%) (its annual reports). Kyntra Bio, Inc. reported 2 product lines in fiscal 2025: Drug Product Revenue at $6 million (91%), Development and Other Revenue at $592 thousand (9%); 0 of 2 grew against the year before (its annual report).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
Did its newest year beat what its own record pointed to?
top 33% of 233 in its family for expectations against reality.
From the record
Kyntra Bio, Inc.'s newest year against its own record: revenue of $6 million in fiscal 2025 came in 52.6% below the $14 million its prior three years' pace pointed to (bottom 18% of its family); net income of $183 million against a prior three-year average of $208 million (top 8%); a net margin of more than its whole revenue against losses larger than its revenue before (top 10%) (its annual reports).
What it rests on
A production reading, recomputed from the filings on every data build, read from EDGAR Nov 13, 2026.
The grade is the company against its own industry, from its filings. It is not a view on the share price. How the grade is made